Halofuginone enhances the anti-tumor effect of ALA-PDT by suppressing NRF2 signaling in cSCC
- 1 March 2022
- journal article
- research article
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 37, 102572
Abstract
No abstract availableKeywords
Funding Information
- Shanghai Municipal Health Commission (ZXYXZ-2019011)
- Shanghai Municipal Natural Science Foundation (21ZR1457100)
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China (31801187, 82073013)
This publication has 27 references indexed in Scilit:
- Cellular Intrinsic Factors Involved in the Resistance of Squamous Cell Carcinoma to Photodynamic TherapyJournal of Investigative Dermatology, 2014
- The chemistry and biology of febrifugine and halofuginoneBioorganic & Medicinal Chemistry, 2014
- Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tractWorld Journal of Gastroenterology, 2014
- European guidelines for topical PDT part 1 JEADV 2013; 27: 536–544Journal of the European Academy of Dermatology and Venereology, 2013
- Factors Predictive of Recurrence and Death From Cutaneous Squamous Cell CarcinomaJAMA Dermatology, 2013
- NRF2 and cancer: the good, the bad and the importance of contextNature Reviews Cancer, 2012
- Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective studyThe Lancet Oncology, 2008
- Treatment of skin cancer and pre-cancer using topical ALA-PDT—A single hospital experiencePhotodiagnosis and Photodynamic Therapy, 2008
- Targeting TGFβ signaling to inhibit fibroblast activation as a therapy for fibrosis and cancer: effect of halofuginoneExpert Opinion on Drug Discovery, 2007
- Incorporating Photodynamic Therapy into a Medical and Cosmetic Dermatology PracticeDermatologic Clinics, 2007